<- Go Home
MedinCell S.A.
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France.
Market Cap
EUR 522.5M
Volume
84.0K
Cash and Equivalents
N/A
EBITDA
-EUR 9.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
EUR 27.7M
Profit Margin
100.00%
52 Week High
EUR 19.00
52 Week Low
EUR 12.00
Dividend
N/A
Price / Book Value
N/A
Price / Earnings
N/A
Price / Tangible Book Value
N/A
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-EUR 10.8M
Return on Equity
N/A
Return on Assets
N/A
Cash and Short Term Investments
N/A
Debt
N/A
Equity
N/A
Revenue
EUR 27.7M
Unlevered FCF
N/A
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium